Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Non-Current Deffered Revenue of $8.7 million for Q1 2026, up 2726.06% quarter-over-quarter from $307000.0 in Q2 2023.
Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Non-Current Deffered Revenue for 5 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (changed N/A YoY), while the FY2022 annual figure was $2.2 million, up 217.29% from the prior year.
- Non-Current Deffered Revenue advanced to $8.7 million in Q1 2026 per JANX's latest filing, from $307000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $8.7 million in Q1 2026 and bottomed at $307000.0 in Q2 2023.
- Historically, Non-Current Deffered Revenue has averaged $3.6 million across 3 years, with a median of $3.0 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue surged 217.29% — and 2023, when it plunged 94.2%.
- Janux Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2022, then slumped by 86.18% to $307000.0 in 2023, then jumped by 2726.06% to $8.7 million in 2026.
- Business Quant data shows JANX's Non-Current Deffered Revenue at $8.7 million in Q1 2026, $307000.0 in Q2 2023, and $1.4 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Mn |
| Mar 31, 2026 | 8.68 Mn |
| Jun 30, 2023 | 307,000.00 |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 3.82 Mn |
| Jun 30, 2022 | 5.29 Mn |
| Dec 31, 2021 | 700,000.00 |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 2.82 Mn |
| Dec 31, 2020 | 6.05 Mn |